Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21789743 | 0.86 | THRA (0.34) | ALOX5ALDH1A1PKMTHRATHRB | |
| SCHEMBL18611353 | 0.83 | ALOX5 (0.35) | ALOX5ALDH1A1PKMTHRATHRB | |
| SCHEMBL23872422 | 0.71 | ALOX5 (0.38) | ALOX5THRATHRB | |
| SCHEMBL15998881 | 0.70 | ALOX5 (0.40) | ALOX5ALDH1A1PKMMLYCD | |
| SCHEMBL23616319 | 0.70 | ALOX5 (0.56) | ALOX5ALDH1A1PKMMLYCD | |
| SCHEMBL21789745 | 0.69 | ALOX5 (0.33) | ALOX5THRATHRB | |
| SCHEMBL16292529 | 0.68 | ALOX5 (0.39) | ALOX5ALDH1A1PKMTHRATHRB | |
| SCHEMBL18611269 | 0.68 | ALOX5 (0.43) | ALOX5ALDH1A1PKMTHRATHRB | |
| SCHEMBL23872657 | 0.68 | ALOX5 (0.35) | ALOX5ALDH1A1PKMTHRATHRB | |
| SCHEMBL23613006 | 0.68 | ALOX5 (0.36) | ALOX5ALDH1A1PKMTHRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053253-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | ALOX5 132/4885ALDH1A1 3904/4885PKM 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.